 |
|
|
| |
Low Persistence of Resistance-Associated Variants After 3 Days of Monotherapy With NS5B NNI Site II Inhibitor GS-9669 in Genotype 1 HCV Patients
|
| |
| |
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Hadas Dvory-Sobol,1 Viktoria Gontcharova,1 Ross Martin,1 Eric J. Lawitz,2 John G. McHutchison,1 Evguenia S. Svarovskaia,1 Michael D. Miller,1 Hongmei Mo1
1Gilead Sciences, Inc., Foster City, California, USA; 2Alamo Medical Research, San Antonio, Texas, USA
|
| |
|
|
|
|
|
